---
title: LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
nct_id: NCT06103682
overall_status: RECRUITING
phase: NA
sponsor: University of California, Davis
study_type: INTERVENTIONAL
primary_condition: Non-small Cell Lung Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06103682.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06103682"
ct_last_update_post_date: 2023-10-31
last_seen_at: "2026-05-12T06:56:19.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

**NCT ID:** [NCT06103682](https://clinicaltrials.gov/study/NCT06103682)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** University of California, Davis
- **Collaborators:** National Cancer Institute (NCI)
- **Conditions:** Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
- **Start Date:** 2023-10-05
- **Completion Date:** 2031-01-05
- **CT.gov Last Update:** 2023-10-31

## Brief Summary

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

## Detailed Description

This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary endpoint is disease control at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy. Participants will receive ablative local therapy per standard practices in addition to their systemic therapy and will be followed for up to 5 years following ablative local therapy. Participants will be assigned stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy per the discretion of treating radiation oncologist and/or interventional radiologist.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:

   1. Cohort A: Non-small cell cancer
   2. Cohort B: Small cell cancer
2. Provision of signed and dated informed consent form.
3. Stated willingness to comply with all study procedures and availability for the duration of the study.
4. Age ≥18 years at time of consent.
5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\]
7. ≤ 5 progressing or new metastatic lesions.
8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.

Exclusion Criteria:

1. Medical comorbidities precluding locally ablative therapies.
2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
3. Progressing intracranial lesions.
```

## Arms

- **Ablative local therapy** (EXPERIMENTAL) — Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

## Interventions

- **Ablative local therapy** (DEVICE) — Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

## Primary Outcomes

- **Number of participants with controlled disease** _(time frame: 3 months from the first day of ablative local therapy)_ — Number of participants with controlled disease at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy

## Secondary Outcomes

- **Number of participants experiencing grade ≥ 3 adverse events attributable to ablative local therapy** _(time frame: Up to 2 years from the first day of ablative local therapy)_
- **Median overall survival** _(time frame: Up to 1 year from the first day of ablative local therapy)_
- **Time to treatment failure** _(time frame: Up to 1 year from the first day of ablative local therapy)_

## Locations (1)

- University of California, Davis, Sacramento, California, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of california, davis|sacramento|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06103682.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06103682*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*